NCT07676448

Brief Summary

Differentiating radiation necrosis from tumor progression in patients with brain metastases has a major therapeutic and prognostic implications

Trial Health

65
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
80

participants targeted

Target at P50-P75 for all trials

Timeline
3mo left

Started Aug 2026

Shorter than P25 for all trials

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

June 24, 2026

Completed
6 days until next milestone

First Posted

Study publicly available on registry

June 30, 2026

Completed
1 month until next milestone

Study Start

First participant enrolled

August 5, 2026

Expected
29 days until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 3, 2026

2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

November 3, 2026

Last Updated

July 17, 2026

Status Verified

July 1, 2026

Enrollment Period

29 days

First QC Date

June 24, 2026

Last Update Submit

July 16, 2026

Conditions

PET-CT

Outcome Measures

Primary Outcomes (1)

  • To compare the diagnostic performance amino acid PET imaging

    Uptake of tumor

    Day 1

Secondary Outcomes (1)

  • To evaluate the potential impact of immunotherapy administered before or during PET imaging

    2 weeks

Interventions

PET exam analysisDIAGNOSTIC_TEST

static and dynamic analyses

Eligibility Criteria

Age18 Years - 90 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

All patients referred for amino acid PET imaging in the Nuclear Medicine Department of Nancy University Hospital for the differential diagnosis between radiation necrosis and brain tumor progression between November 1, 2018, and April 30, 2026.

You may qualify if:

  • Patients who received a PET amino acid for differentiating radiation necrosis from progression of irradiated brain metastases,

You may not qualify if:

  • Patients who refused the using of their data

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Officials

  • Antoine AV VERGER, MD, PhD

    NANCY HOSPITAL

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Lucas LW WILHELM, MD

CONTACT

0383153911l.wilhelm@chru-nancy.fr

Veronique VR Roch, MSc

CONTACT

0383154276v.roch@chru-nancy.fr

Study Design

Study Type
observational
Observational Model
OTHER
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Prinicipal Investigator

Study Record Dates

First Submitted

June 24, 2026

First Posted

June 30, 2026

Study Start (Estimated)

August 5, 2026

Primary Completion (Estimated)

September 3, 2026

Study Completion (Estimated)

November 3, 2026

Last Updated

July 17, 2026

Record last verified: 2026-07